Tropisetron HCl Clinical Trials

Size	Price	Qty
10mg	USD 97

Clinical Trials

A Phase 4 interventional clinical trial, sponsored by Beijing Chao Yang Hospital, evaluates the efficacy of Tropisetron for the prevention of postoperative cognitive dysfunction and postoperative delirium. Currently of unknown recruitment status, this active investigation reflects an ongoing effort to expand Tropisetron's clinical application beyond standard antiemetic care. Ultimately, the trial seeks to demonstrate its potential in mitigating central nervous system impairment in surgical patients.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04195204	Unknown status	Postoperative Cognitive Dysfunction\|Postoperative Delirium	Beijing Chao Yang Hospital	2020-11-01	Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Tropisetron HCl product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Tropisetron HCl acts as a selective 5-HT3 receptor antagonist and α7-nicotinic acetylcholine receptor agonist, thereby inhibiting serotonin-mediated synaptic depolarization while promoting cholinergic neuroprotective pathways. This dual receptor modulation attenuates emetic signal transmission and dampens neuroinflammatory signaling, providing a mechanistically rational approach for preventing postoperative cognitive dysfunction and postoperative delirium.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).